欧康维视生物-B(01477)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01477 欧康维视生物-B

未开盘 04-29 16:08:37

7.500

+0.050

+0.67%

最高7.550	最低7.400	成交量30.40万
今开7.450	昨收7.450	日振幅2.01%
总市值61.13亿	流通市值61.13亿	总股本8.15亿
成交额227.38万	换手率0.04%	流通股本8.15亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01477","market":"HK","secType":"STK","nameCN":"欧康维视生物-B","latestPrice":7.5,"timestamp":1777450117003,"preClose":7.45,"halted":0,"volume":304000,"delay":0,"changeRate":0.00671140939597313,"floatShares":815000000,"shares":815000000,"eps":-0.22890438871473356,"marketStatus":"未开盘","change":0.05,"latestTime":"04-29 16:08:37","open":7.45,"high":7.55,"low":7.4,"amount":2273765,"amplitude":0.020134,"askPrice":7.51,"askSize":2500,"bidPrice":7.5,"bidSize":14500,"shortable":3,"etf":0,"ttmEps":-0.22890438871473356,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1777512600000},"marketStatusCode":0,"adr":0,"listingDate":1594310400000,"exchange":"SEHK","adjPreClose":7.45,"openAndCloseTimeList":[[1777426200000,1777435200000],[1777438800000,1777449600000]],"volumeRatio":0.5677111305641912,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01477","defaultTab":"news","newsList":[{"id":"2631516845","title":"复旦张江（688505）披露将参加科创板制药行业集体业绩说明会，4月29日股价上涨1.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631516845","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631516845?lang=zh_cn&edition=full","pubTime":"2026-04-29 19:53","pubTimestamp":1777463583,"startTime":"0","endTime":"0","summary":"截至2026年4月29日收盘，复旦张江报收于7.75元，较前一交易日上涨1.17%，最新总市值为80.33亿元。复旦张江于近日披露《关于参加十五五·科创惠民—科创板企业成果转化与民生赋能之2025年度制药行业集体业绩说明会的公告》。公司已于2026年3月31日披露2025年年度报告。说明会结束后，投资者可通过上证路演中心查看会议情况。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900060896.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159982","BK0239","01349","01477","BK1191","BK1574","688505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631980325","title":"香雪制药2025年归母净亏损13.92亿元，中药材收入占比升至61.33%成营收主力","url":"https://stock-news.laohu8.com/highlight/detail?id=2631980325","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631980325?lang=zh_cn&edition=full","pubTime":"2026-04-29 17:06","pubTimestamp":1777453612,"startTime":"0","endTime":"0","summary":"数据显示，公司2025年实现营业收入15.95亿元，同比减少14.16%；归母净利润为-13.92亿元，同比减少62.15%；扣非净利润为-10.68亿元，同比减少30.37%。2025年第四季度单季营业收入为4.49亿元，归母净利润为-10.30亿元，扣非净利润为-7.57亿元，三项指标均呈现显著季节性恶化；归母净利润占全年亏损的74.01%，扣非净利润占比70.89%，表明年末集中确认大额非经常性损失进一步加剧全年业绩失衡。中药材收入占比升至61.33%，医药制造收入占比为17.72%，二者合计占总收入近八成。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1777448230550998460","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631562933","title":"技术突破、资本破冰、临床攻坚，广东AI制药闯关“死亡谷”","url":"https://stock-news.laohu8.com/highlight/detail?id=2631562933","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631562933?lang=zh_cn&edition=full","pubTime":"2026-04-29 15:46","pubTimestamp":1777448804,"startTime":"0","endTime":"0","summary":"医药界流传着一条残酷的“双十定律”：研发周期超十年、投入超十亿美元，成功率却不足10%。这是创新药研发长期面临的困境，也是投资人对早期项目望而却步的根本原因。AI辅助制药正在改变这一局面，大幅缩短药物发现周期，提升研发效率。近期，剂泰科技、德睿智药等中外企业相继宣布，其AI主导设计的产品已进入III期临床试验阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604293724365890.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604293724365890.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","AIPO","01477","CHAT","AGIX","ARTY","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161900449","title":"欧康维视生物-B2025年营收大涨92.8%至8.04亿元 研发投入稳步推进 亏损显著收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=1161900449","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161900449?lang=zh_cn&edition=full","pubTime":"2026-04-28 17:14","pubTimestamp":1777367693,"startTime":"0","endTime":"0","summary":"欧康维视生物-B于2025年实现营业收入8.04亿元人民币，较2024年度的4.17亿元人民币同比增长92.8%。毛利相应上升至3.61亿元人民币，较去年同期增长60.4%。在销售成本增加至4.43亿元人民币的同时，公司整体盈利能力有所改善，2025年度除税前亏损1.58亿元人民币，较上年同期的2.67亿元人民币收窄40.7%，年内亏损亦降至1.59亿元人民币，每股基本及摊薄亏损从上年的0.39元人民币降至0.20元人民币。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"欧康维视生物-B2025年营收大涨92.8%至8.04亿元 研发投入稳步推进 亏损显著收窄","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630397093","title":"荣昌生物（688331）披露将参加2025年度制药行业集体业绩说明会，4月27日股价上涨1.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630397093","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630397093?lang=zh_cn&edition=full","pubTime":"2026-04-27 22:04","pubTimestamp":1777298696,"startTime":"0","endTime":"0","summary":"截至2026年4月27日收盘，荣昌生物报收于135.05元，较前一交易日上涨1.52%，最新总市值为762.33亿元。近日，荣昌生物发布《关于参加十五五·科创惠民——科创板企业成果转化与民生赋能之2025年度制药行业集体业绩说明会的公告》。公告显示，公司将于2026年5月11日15:00-17:00参加由上海证券交易所组织举办的上述集体业绩说明会，通过上证路演中心网络文字互动方式与投资者交流。公司将就2025年度经营成果、财务状况等投资者关注的问题进行回应。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700045397.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK1161","688331","BK1583","LU2148510915.USD","09995","LU1064130708.USD","BK0239","BK1191","LU1969619763.USD","LU1064131003.USD","LU2488822045.USD","LU2328871848.SGD","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630392866","title":"利甘制药近 7.4 亿美元收购佐马公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2630392866","media":"环球市场播报","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630392866?lang=zh_cn&edition=full","pubTime":"2026-04-27 21:15","pubTimestamp":1777295700,"startTime":"0","endTime":"0","summary":"　　利甘制药宣布，已达成协议，斥资约7.4 亿美元收购生物科技特许权投资企业佐马特许权公司。　　根据协议条款，利甘将以每股 39 美元的现金价格收购佐马股票，较其上周五 37.90 美元的收盘价溢价 2.9%。　　利甘上调 2026 年营收预期，从此前的 2.45 亿至 2.85 亿美元，调整至2.7 亿至 3.1 亿美元。　　盘前交易阶段，利甘制药股价上涨 3.9%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-04-27/doc-inhvyefa7726457.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1191","BK1574","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630332792","title":"歌礼制药-B(01672)宣布口服小分子GLP-1R激动剂ASC30治疗糖尿病的美国II期研究完成入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2630332792","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630332792?lang=zh_cn&edition=full","pubTime":"2026-04-27 08:09","pubTimestamp":1777248561,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B 发布公告，其评估口服小分子GLP-1受体 激动剂ASC30治疗2型糖尿病的13周美国II期研究已完成入组。预计将于2026年第3季度获得该项治疗2型糖尿病的II期研究的顶线数据。由歌礼自主研发的ASC30是首款也是唯一一款正在临床研究中的、既可每日一次口服也可每月一次至每季度一次皮下注射的小分子GLP-1R完全偏向激动剂，用于肥胖症、糖尿病及其它代谢疾病的治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1434121.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01477","BK1515","GLP","BK1161","BK1574","BK4590","01672","BK1191","BK4144"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630326673","title":"太阳制药将以每股14美元现金收购欧加农 交易企业估值达117.5亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2630326673","media":"环球市场播报","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630326673?lang=zh_cn&edition=full","pubTime":"2026-04-27 07:59","pubTimestamp":1777247940,"startTime":"0","endTime":"0","summary":"太阳制药将以全现金方式，按每股 14 美元价格收购欧加农全部流通股份，本次交易企业估值达 117.5 亿美元。该交易已获得太阳制药与欧加农双方董事会批准。太阳制药计划结合自有流动资金及银行承诺融资，为本次收购提供资金。交易预计于 2027 年初完成，尚需通过监管审批、欧加农股东投票等常规成交条件。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：王永生","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-04-27/doc-inhvwwmp2484295.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["01477","BK1574","BK1191","UDN","UUP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629894566","title":"创新药概念持续拉升 海西新药(02637)领涨12.77%、歌礼制药-B(01672)涨6.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629894566","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629894566?lang=zh_cn&edition=full","pubTime":"2026-04-24 13:11","pubTimestamp":1777007494,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念午后集体持续拉升，截至发稿，海西新药 涨12.77%，歌礼制药-B涨6.27%，诺诚健华涨5.18%，信达生物涨4.10%，科伦博泰生物涨2.84%，亚盛医药-B涨2.79%。西南证券亦表示，医药生物行业近期表现虽相对疲软，估值溢价率有所下降，但行业整体仍保持一定韧性。其他生物制品、医疗研发外包和原料药等细分领域表现突出，显示出医药创新和产业链优势的持续释放。","market":"us","thumbnail":"https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1979909","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0196878994.USD","BK1589","LU2097828805.USD","LU2097828631.EUR","LU2097828474.EUR","LU1969619763.USD","BK1515","06855","02637","06978","BK1583","BK1574","LU2097828714.EUR","LU2328871848.SGD","159992","HK0000165453.HKD","LU0455707207.USD","LU2488822045.USD","BK1161","01477","BK1191","LU2242644610.SGD","LU0502904849.HKD","01672","01801","06990","LU2097828557.USD","09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629896382","title":"港股异动 | 歌礼制药-B(01672)午前涨超4% 核心管线ASC30即将启动III期注册临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2629896382","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629896382?lang=zh_cn&edition=full","pubTime":"2026-04-24 11:10","pubTimestamp":1777000213,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，歌礼制药-B午前涨超4%，截至发稿，涨3.46%，报18.82港元，成交额2199.1万港元。消息面上，歌礼制药此前宣布启动ASC30_39FDC的临床开发，并计划于今年第三季度向美国FDA递交IND申请。口服剂型即将向FDA提交III期临床计划，公司预计将在2026年Q3正式启动。值得注意的是，智通财经APP在《歌礼制药-B：股价突破前高在即，场外资金为何选择观望？》中指出，礼来Orforglipron已于今年4月1日获FDA批准上市。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1433212.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK4134","BK4585","BK1191","01672","01477","BK4588","III","BK1161","BK1574","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629830726","title":"泽璟制药（688266）披露将参加2025年度制药行业集体业绩说明会，4月23日股价下跌3.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629830726","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629830726?lang=zh_cn&edition=full","pubTime":"2026-04-23 22:05","pubTimestamp":1776953123,"startTime":"0","endTime":"0","summary":"截至2026年4月23日收盘，泽璟制药报收于98.0元，较前一交易日下跌3.14%，最新总市值为259.41亿元。近日，泽璟制药发布《关于参加十五五·科创惠民——科创板企业成果转化与民生赋能之2025年度制药行业集体业绩说明会的公告》。公告显示，公司将于2026年5月11日15:00-17:00通过上证路演中心网络互动方式参加由上海证券交易所主办的上述集体业绩说明会。公司将就2025年年度报告涉及的经营成果、财务状况等投资者关注问题进行解答。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042300061779.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK0239","01477","688266","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629022259","title":"艾伯维斥资14亿美元在北卡罗来纳州建制药园区","url":"https://stock-news.laohu8.com/highlight/detail?id=2629022259","media":"环球市场播报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629022259?lang=zh_cn&edition=full","pubTime":"2026-04-23 03:32","pubTimestamp":1776886320,"startTime":"0","endTime":"0","summary":"2026年4月22日，全球生物制药巨头艾伯维公司宣布了一项重大投资计划，将斥资14亿美元在美国北卡罗来纳州达勒姆市建设一个全新的制药制造园区。这是该公司迄今为止在单一地点进行的最大规模投资。　　根据规划，这座占地185英亩的新园区将成为艾伯维在美国主要的注射药物生产基地，旨在扩大其国内产能，以满足全球市场对关键药物的需求。　　此项投资是艾伯维未来十年在美国投入约1000亿美元用于研发和制造宏伟计划的重要组成部分。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-04-23/doc-inhvmmmn5225636.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1191","01477","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629700085","title":"凯莱英：拥有连续性反应等核心制药技术的自主知识产权","url":"https://stock-news.laohu8.com/highlight/detail?id=2629700085","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629700085?lang=zh_cn&edition=full","pubTime":"2026-04-21 15:54","pubTimestamp":1776758052,"startTime":"0","endTime":"0","summary":"证券之星消息，凯莱英04月21日在投资者关系平台上答复投资者关心的问题。公司拥有连续性反应等核心制药技术的自主知识产权，是世界上为数不多的将连续性反应技术延伸应用在大规模生产制造的公司之一，并持续提升连续性反应以及各项新技术在临床中后期项目中的应用率。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042100033830.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1191","002821","BK0239","06821","BK0132","LU1328615791.USD","01477","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628745559","title":"科伦药业：公司持有海南普利制药股份有限公司股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2628745559","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628745559?lang=zh_cn&edition=full","pubTime":"2026-04-20 17:00","pubTimestamp":1776675628,"startTime":"0","endTime":"0","summary":"证券之星消息，科伦药业(002422)04月20日在投资者关系平台上答复投资者关心的问题。投资者提问：贵司是持有普利制药股票还是债券？谢谢科伦药业回复：投资者您好，公司持有海南普利制药股份有限公司股权。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。相关 ETF","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042000022697.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2148510915.USD","BK0060","01477","BK0239","LU1979443071.USD","BK1574","LU1064131003.USD","LU1934453819.USD","BK1191","002422","LU1064130708.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628711742","title":"制药界的Space X来了，剂泰科技通过聆讯，冲刺“AI药物递送第一股”","url":"https://stock-news.laohu8.com/highlight/detail?id=2628711742","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628711742?lang=zh_cn&edition=full","pubTime":"2026-04-20 14:10","pubTimestamp":1776665407,"startTime":"0","endTime":"0","summary":"一个不同于靶点发现的叙事样本","market":"sh","thumbnail":"https://img2.gelonghui.com/6c8ee-bf7bb5e5-3101-4faa-8201-46ed154478bd.jpg?guru_height=855&guru_width=1458&guru_size=220020","type":0,"news_type":0,"thumbnails":["https://img2.gelonghui.com/6c8ee-bf7bb5e5-3101-4faa-8201-46ed154478bd.jpg?guru_height=855&guru_width=1458&guru_size=220020"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/4473843","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK1191","SOCL","CHAT","BK1574","01477","AIPO","AGIX","ARTY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628679061","title":"新股解读 ｜ 制药界“SpaceX”启航：AI药物递送第一股，剂泰科技开启生物制药递送时代","url":"https://stock-news.laohu8.com/highlight/detail?id=2628679061","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628679061?lang=zh_cn&edition=full","pubTime":"2026-04-20 09:16","pubTimestamp":1776647792,"startTime":"0","endTime":"0","summary":"在这一背景下，剂泰科技于近日正式通过港交所聆讯，作为“全球AI药物递送第一股”，剂泰科技的出现不仅是AI制药赛道的一个里程碑，更标志着人工智能对生物医药的赋能已经从分子发现延伸到了更为底层、更具壁垒的大分子递送领域。打造制药界的“SpaceX”与底层系统供应商在商业化逻辑上，剂泰科技采取了“平台合作+管线授权”双轨并行的商业模式，旨在实现价值最大化。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430468.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","UFO","ARTY","AGIX","DXYZ","BK1191","CHAT","XOVR","01477","AIPO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628536739","title":"歌礼制药-B(01672)：股价突破前高在即，场外资金为何选择观望？","url":"https://stock-news.laohu8.com/highlight/detail?id=2628536739","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628536739?lang=zh_cn&edition=full","pubTime":"2026-04-18 12:36","pubTimestamp":1776486970,"startTime":"0","endTime":"0","summary":"股价突破前高在即，场外资金却选择观望?但在3月30日，歌礼制药交出2025年成绩单后，二级市场却出现“三连阴”放缓了公司股价后续的上攻势头。导致歌礼制药在2025年“增收不增利”的主要原因在于当期研发费用暴增。并且根据最新信息，礼来Orforglipron已于今年4月1日获FDA批准上市，成为全球首个口服小分子非肽类GLP-1减重药。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430290.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01672","BK1574","01477","BK1161","BK1515","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628927838","title":"港股异动 | 歌礼制药-B(01672)午后涨近5% 股价逼近历史前高 GLP-1+胰淀素复方制剂启动临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2628927838","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628927838?lang=zh_cn&edition=full","pubTime":"2026-04-17 14:28","pubTimestamp":1776407328,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，歌礼制药-B午后涨近5%，高见18.68港元，逼近历史前高18.75港元。消息面上，歌礼制药近日公告，口服小分子GLP-1受体激动剂与口服小分子胰淀素受体激动剂固定剂量复方制剂ASC30_39FDC全面启动临床开发。值得关注的是，这是全球首个公开宣布的口服小分子GLP-1与口服小分子胰淀素固定剂量复方制剂，标志着歌礼在代谢疾病领域的创新布局实现关键突破。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1429849.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK4144","01672","BK4585","BK1161","BK4588","BK4590","VXUS","BK1191","GLP","BK1515","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628221164","title":"港股异动 | CXO 概念股跌幅居前 海外投融资大环境进入波动阶段 AI制药或导致研发及临床端分化","url":"https://stock-news.laohu8.com/highlight/detail?id=2628221164","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628221164?lang=zh_cn&edition=full","pubTime":"2026-04-17 11:31","pubTimestamp":1776396664,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，CXO概念股跌幅居前，截至发稿，昭衍新药跌5.82%，报21.7港元；康龙化成跌3.65%，报21.1港元；泰格医药跌3.02%，报42.46港元。中信建投发布研报称，海外投融资大环境进入季度间波动，不同阶段、不同疾病领域的CXO服务需求进一步分化，国内投融资活动景气度持续上行，弹性更强，持续看好CXO板块成长空间。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1429805.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","CXO","03347","BK4585","03759","06127","BK1141","BK1191","BK1583","CHAT","BK1576","ARTY","01477","BK4588","AGIX","AIPO","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627293848","title":"印度Hetero制药司美格鲁肽笔全球推广目标年销量150万支","url":"https://stock-news.laohu8.com/highlight/detail?id=2627293848","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627293848?lang=zh_cn&edition=full","pubTime":"2026-04-16 16:44","pubTimestamp":1776329040,"startTime":"0","endTime":"0","summary":"　　印度大型私营制药企业之一 Hetero 实验室公司一名高管表示，该公司计划未来数年在超 75 个国家推出仿制版减肥及糖尿病药物，首年目标销量达 150 万支注射笔。　　Hetero 董事总经理瓦姆西克里希纳班迪 3 月接受路透社采访时称，公司计划 4 月在印度本土上市该药物，初期将重点拓展海外市场份额。　　其规模更大的竞争对手雷迪博士实验室已宣布，首年目标销量为 1200 万支；而 MSN 实验室等中小型药企则计划在印度本土首年实现 10 万支的销量目标。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-04-16/doc-inhusvke3927022.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["01477","BK1191","MNDmain","BK1574"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ocumension.com","stockEarnings":[{"period":"1week","weight":-0.0347},{"period":"1month","weight":-0.0092},{"period":"3month","weight":0.0417},{"period":"6month","weight":-0.1018},{"period":"1year","weight":0.3838},{"period":"ytd","weight":0.0135}],"compareEarnings":[{"period":"1week","weight":-0.002},{"period":"1month","weight":0.055},{"period":"3month","weight":-0.0664},{"period":"6month","weight":0.0079},{"period":"1year","weight":0.1865},{"period":"ytd","weight":0.0188}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"欧康维视生物是一家主要从事眼科药物的研发和商业化的公司。该公司产品主要包括OT-401“优施莹”氟轻松玻璃体内植入剂、OT-702“博优景”阿柏西普眼内注射溶液、OT-402“维速达尔”注射用维替泊芬、OT-204“欧沁”玻璃酸钠滴眼液及OT-305“贝特舒”盐酸倍他洛尔滴眼液等。该公司产品主要用于治疗葡萄膜炎、眼底疾病、屈光矫正、干眼症（DED）、青光眼及角结膜炎等各种眼前及眼后段疾病。该公司主要在中国国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.166667,"avgChangeRate":-0.097698},{"month":2,"riseRate":0.5,"avgChangeRate":-0.037557},{"month":3,"riseRate":0.5,"avgChangeRate":0.044668},{"month":4,"riseRate":0.5,"avgChangeRate":0.017903},{"month":5,"riseRate":0.6,"avgChangeRate":0.137077},{"month":6,"riseRate":0.8,"avgChangeRate":0.129408},{"month":7,"riseRate":0.4,"avgChangeRate":-0.027707},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.064893},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.082685},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.121217},{"month":11,"riseRate":0.333333,"avgChangeRate":0.004503},{"month":12,"riseRate":0.5,"avgChangeRate":0.058088}],"exchange":"SEHK","name":"欧康维视生物-B","nameEN":"OCUMENSION-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"欧康维视生物-B(01477)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供欧康维视生物-B(01477)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"欧康维视生物-B,01477,欧康维视生物-B股票,欧康维视生物-B股票老虎,欧康维视生物-B股票老虎国际,欧康维视生物-B行情,欧康维视生物-B股票行情,欧康维视生物-B股价,欧康维视生物-B股市,欧康维视生物-B股票价格,欧康维视生物-B股票交易,欧康维视生物-B股票购买,欧康维视生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"欧康维视生物-B(01477)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供欧康维视生物-B(01477)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}